Company intelligence / Profile preview

Nyegaard & Co.

Ownership: Private
Development stage: Other

Overview

Nyegaard & Co. was a Norwegian pharmaceutical company founded in 1874 that became internationally recognized for its research-driven approach and innovation in diagnostic imaging products. Its most notable product was Amipaque, a nonionic X-ray contrast agent developed in 1969, followed by Omnipaque. The company's success led to international expansion and eventual acquisition by larger entities. In the mid-to-late 1990s, it merged with British Amersham after being renamed Hafslund Nycomed.

Therapeutic areas: Other
Modalities: Small moleculeContrast media agents
Industry: Medical Imaging

Partnerships

Engaged licensing agreements for international marketing/distribution of contrast agents.

Beyond the preview

Go deeper on Nyegaard & Co..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Nyegaard & Co..

Explore the full profile